EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Ko-Hsiu Lu iD, Renn-Chia Lin iD, Ing-Lin Chang iD, Shau-Huai Fu iD, Meng-Ying Tsai iD, Shun-Fa Yang iD

Clinical Pharmacology & Therapeutics · 2026-08 · 120 (2) · 334-344

DOI: 10.1002/cpt.70323 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 08.05.2026. Verfasst von Ko-Hsiu Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality. This review addresses three key clinical considerations: (1) the mechanistic and clinical evidence for rebound effects and indications for Dmab cessation (“Why?”); (2) patient populations in whom Dmab initiation or continuation may be inappropriate and who therefore require careful transition planning (“For whom?”); and (3) optimal discontinuation and sequential treatment strategies, including scenarios in which continued or lifelong therapy may be advisable (“How?”). Emerging data suggest that concurrent teriparatide and zoledronate may attenuate rebound risk in long‐term Dmab users requiring urgent discontinuation, although prospective validation is needed before routine adoption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBone Density Conservation AgentsHumansTreatment InterruptionTeriparatideTime Factors

Substanzen

DenosumabBone Density Conservation AgentsTeriparatide

Autor:innen und Institutionen

  • Department of Orthopedics, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Orthopaedic Surgery, Changhua Christian Hospital, Changhua, Taiwan.
  • Department of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Douliu, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.

ORCID-Profile: Ko-Hsiu Lu, Renn-Chia Lin, Ing-Lin Chang, Shau-Huai Fu, Meng-Ying Tsai, Shun-Fa Yang

Zitieren

APA

Lu, K. H., Lin, R. C., Chang, I. L., Fu, S. H., Tsai, M. Y., & Yang, S. F. (2026). Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?. Clinical Pharmacology & Therapeutics, 120(2), 334-344. https://doi.org/10.1002/cpt.70323

Vancouver

Lu KH, Lin RC, Chang IL, Fu SH, Tsai MY, Yang SF. Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?. Clinical Pharmacology & Therapeutics. 2026;120(2):334-344. doi:10.1002/cpt.70323

BibTeX
@article{Lu2026,
  author = {Lu, Ko-Hsiu and Lin, Renn-Chia and Chang, Ing-Lin and Fu, Shau-Huai and Tsai, Meng-Ying and Yang, Shun-Fa},
  title = {Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {2},
  pages = {334--344},
  doi = {10.1002/cpt.70323}
}
Kostenlos starten →